PRESS RELEASE : Evotec SE to announce results for the first half-year 2021 on 11 August 2021

DGAP-News: Evotec SE / Key word(s): Miscellaneous Evotec SE to announce results for the first half-year 2021 on 11 August 2021 2021-08-04 / 11:00 The issuer is solely responsible for the content of this announcement. -----------------------------------------------------------------------------------------------------------------------

Hamburg, Germany, 04 August 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) will announce its financial results for the first half-year 2021 on Wednesday, 11 August 2021.

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. Conference call details Date: Wednesday, 11 August 2021 Time: 02.00 pm CEST (08.00 am EST, 01.00 pm GMT) From Germany: [phone] From France: [phone] From Italy: [phone] From UK: [phone] From USA: [phone] Access Code: 67644285#

A simultaneous slide presentation for participants dialling in via phone is available at https://www.webcast-eqs.com /evotec20210811/no-audio. Webcast details To join the audio webcast and to access the presentation slides you will find a link on our homepage www.evotec.com shortly before the event.

A replay of the conference call will be available for seven days and can be accessed from Germany by dialling [phone], from UK by dialling [phone] and from USA by dialling [phone].

The access code is 315614525#. The on-demand version of the webcast will be available on our website: https:// www.evotec.com/financial-reports. ABOUT EVOTEC SE Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients. The Company's multimodality platform comprises a unique combination of innovative technologies, data and science for the discovery, development, and production of first-in-class and best-in-class pharmaceutical products. Evotec leverages this "Data-driven R&D Autobahn to Cures" for proprietary projects and within a network of partners including all Top 20 Pharma and over 800 biotechnology companies, academic institutions, as well as other healthcare stakeholders. Evotec has strategic activities in a broad range of currently underserved therapeutic areas, including e.g. neurology, oncology, as well as metabolic and infectious diseases. Within these areas of expertise, Evotec aims to create the world-leading co-owned pipeline for innovative therapeutics and has to-date established a portfolio of more than 200 proprietary and co-owned R&D projects from early discovery to clinical development. Evotec operates globally with more than 3,900 highly qualified people. The Company's 14 sites offer highly synergistic technologies and services and operate as complementary clusters of excellence. For additional information please go to www.evotec.com and follow us on Twitter @Evotec and LinkedIn.

FORWARD-LOOKING STATEMENTS This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding completion of the offering. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. -----------------------------------------------------------------------------------------------------------------------

2021-08-04 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de ----------------------------------------------------------------------------------------------------------------------- Language: English Company: Evotec SE

Manfred Eigen Campus / Essener Bogen 7

22419 Hamburg

Germany Phone: [phone] Fax: [phone] E-mail: [e-mail] Internet: www.evotec.com ISIN: DE0005664809 WKN: 566480 Indices: MDAX, TecDAX Listed: Regulated Market in Berlin, Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf,

Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1223795 End of News DGAP News Service -------------

1223795 2021-08-04

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1223795&application_name=news

(END) Dow Jones Newswires

August 04, 2021 05:00 ET (09:00 GMT)